A 38-year-old woman presents with persistent depressed mood, anhedonia, and insomnia for the past 3 weeks. She denies suicidal ideation but reports significant functional impairment at work. She has no prior psychiatric history and no medical comorbidities. Physical examination and baseline investigations are normal. What is the most appropriate next step in management?

Explanation

## Management of First-Episode Major Depressive Disorder ### Clinical Context This patient presents with a first episode of Major Depressive Disorder (MDD) with: - Core symptoms present (depressed mood, anhedonia, insomnia) - Duration ≥2 weeks (diagnostic threshold met) - Functional impairment - **No suicidal ideation** (no acute safety concern) - Normal physical and baseline investigations ### Rationale for SSRI + Psychotherapy **Key Point:** First-line pharmacological treatment for MDD is an SSRI (or SNRI), combined with psychotherapy for optimal outcomes. **High-Yield:** The combination of antidepressant + psychotherapy (CBT, IPT, or supportive) is superior to either modality alone in first-episode MDD. **Clinical Pearl:** SSRIs are preferred over tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) due to: - Better tolerability and safety profile - Lower lethality in overdose - Fewer drug–drug interactions - Easier titration ### Timeline and Expectations - Onset of action: 2–4 weeks (some improvement may occur by week 2) - Full response: 6–8 weeks - Weekly psychotherapy sessions during initial phase support engagement and monitoring ### Why Outpatient Management Is Appropriate Here - No active suicidal/homicidal ideation - Adequate social support (employed, no mention of isolation) - No acute medical comorbidity - Patient is a candidate for outpatient pharmacotherapy --- ## Comparison of Management Options | Approach | Indication | Rationale | |----------|-----------|----------| | **SSRI + Psychotherapy** | First-episode MDD, mild–moderate severity, no safety risk | **Gold standard**; evidence-based; best long-term outcomes | | Psychiatric admission | Suicidal/homicidal ideation, severe functional collapse, self-care failure | Not indicated here | | Benzodiazepine monotherapy | Acute anxiety/agitation; **NOT** first-line for MDD | Risk of dependence; no antidepressant effect; contraindicated as monotherapy | | Brain imaging | Atypical presentation, focal neurological signs, suspected organic cause | Not indicated in straightforward first-episode MDD | **Tip:** Remember that benzodiazepines may be *added* briefly (2–4 weeks) for anxiety or insomnia, but they are never monotherapy for depression. --- ## Key Guideline Points **Mnemonic: SSRI-FIRST** — **S**elective serotonin reuptake inhibitor, **S**upport (psychotherapy), **R**egular follow-up, **I**nvestigate only if atypical, **F**ull dose after titration, **I**mprovement expected by week 6–8, **R**eassess and switch if no response, **S**upport continuity, **T**reat comorbidity. [cite:Harrison 21e Ch 470] [cite:DSM-5-TR] [cite:Maudsley Guidelines 2023]